Claudine Isaacs

Professor of Medicine

Georgetown University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Claudine Isaacs is a Professor of Medicine at Georgetown University in the United States. Her research focuses on breast cancer treatment strategies, including neoadjuvant therapy and the management of treatment-related side effects. Recent publications highlight her work on hyperglycemia management, exercise interventions for cancer-related fatigue, and the development of decision-support tools for cancer management.

Articles (11)

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (6)

Fei Shen

Indiana University Bloomington

UNITED STATES

View details

Jinani Jayasekera

University of Michigan

UNITED STATES

View details

Paula Pohlmann

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Joseph A. Sparano

Albert Einstein College of Medicine

UNITED STATES

View details

Gillian Hirst

Assistant Professor

University of California, San Francisco

UNITED STATES

View details

Douglas Yee

University of Minnesota

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Claudine Isaacs

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor

An 8-week exercise study to improve cancer treatment related fatigue and QOL among African American breast cancer patients undergoing radiation treatment: A pilot randomized clinical trial

BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions

Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes

Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer

Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores

Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer

Collaborators (6)

Fei Shen

Jinani Jayasekera

Paula Pohlmann

Joseph A. Sparano

Gillian Hirst

Douglas Yee

Make your next move.